Emtricitabine prodrugs with improved anti-hiv activity and cellular uptake

Molecular Pharmaceutics

Volumn 10, Issue 2, 2013, Pages 467-476

  Agarwal, Hitesh K ^a   Chhikara, Bhupender S ^a   Bhavaraju, Sitaram ^a   Mandal, Dindyal ^a   Doncel, Gustavo F ^b   Parang, Keykavous ^a  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

( ) 2 ,3 dideoxy 5 fluoro 3 thiacytidine; anti HIV; cellular uptake; cytotoxicity; fatty acids

Indexed keywords

5' O MYRISTOYL EMTRICITABINE; 5' O(12 AZIDODODECANOYL)EMTRICITABINE; 5' O(12 THIOETHYLDODECANOYL)EMTRICITABINE; BETA ALANINE; EMTRICITABINE; LONG CHAIN FATTY ACID; MYRISTIC ACID; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PRODRUG; UNCLASSIFIED DRUG;

ACYLATION; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG HYDROLYSIS; DRUG POTENCY; DRUG SYNTHESIS; DRUG UPTAKE; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; INCUBATION TIME; INTRACELLULAR TRANSPORT; LYMPHOBLASTOID CELL LINE; NONHUMAN; PRIORITY JOURNAL;

ANTI-HIV AGENTS; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEOXYCYTIDINE; FLOW CYTOMETRY; HIV-1; HUMANS; PRODRUGS;

EID: 84873390479     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp300361a     Document Type: Article

References (28)

1. Saag, M. S. Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus Clin. Infect. Dis. 2006, 42, 126-131 (Pubitemid 41832091)
2. Nelson, M.; Schiavone, M. Emtricitabine (FTC) for the treatment of HIV infection Int. J. Clin. Pract. 2004, 58, 504-510 (Pubitemid 38786573)
3. Wang, L. H.; Begley, J.; St. Claire, R. L., 3rd; Harris, J.; Wakeford, C.; Rousseau, F. S. Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection AIDS Res. Hum. Retroviruses 2004, 20, 1173-1182 (Pubitemid 39557868)
4. Masho, S. W.; Wang, C. L.; Nixon, D. E. Review of tenofovir-emtricitabine Ther. Clin. Risk Manage. 2007, 3, 1097-1104
5. Agarwal, H. K.; Loethan, K.; Mandal, D.; Gustavo, D. F.; Parang, K. Synthesis and biological evaluation of fatty acyl ester derivatives of 2′,3′-didehydro-2′,3′-dideoxythymidine Bioorg. Med. Chem. Lett. 2011, 7, 1917-1921
6. Agarwal, H. K.; Chhikara, B. S.; Doncel, G. F.; Parang., K. Synthesis and anti-HIV activities of glutamate and peptide conjugates of nucleoside reverse transcriptase inhibitors J. Med. Chem. 2012, 55, 2672-2687
7. Paintsil, E.; Grill, S. P.; Dutschman, G. E. Cheng, Chi. Comparative study of the persistence of anti-HIV activity of deoxynucleoside HIV reverse transcriptase inhibitor after removal from culture AIDS Res. Ther. 2009, 6, 5
8. Diallo, K.; Götte, M.; Wainberg1, M. A. Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase Antimicrob. Agents Chemother. 2003, 47, 3377-3383 (Pubitemid 37345693)
9. Mulder, L. C. F.; Harari, A.; Simon, V. Cytidine deamination induced HIV-1 drug resistance Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 5501-5506 (Pubitemid 351753892)
10. Sarafianos, S. G.; Das, K.; Clark, A. D., Jr.; Ding, J.; Boyer, P. L.; Hughes, S. H.; Arnold, E. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with b-branched amino acids Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 10027-10032 (Pubitemid 29422506)
11. Das, K.; Xiong, X.; Yang, H.; Westland, C. E.; Gibbs, C. S.; Sarafianos, S. G.; Arnold, E. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis b virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC) J. Virol. 2001, 75, 4771-4779 (Pubitemid 32381520)
12. Borroto-Esoda, K.; Vela, J. E.; Myrick, F.; Ray, A. S.; Miller, M. D. In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine Antiviral Ther. 2006, 11, 377-384 (Pubitemid 43823557)
13. Gallant, J. E.; DeJesus, E.; Arribas, J. R.; Pozniak, A. L.; Gazzard, B.; Campo, R. E.; Lu, B.; McColl, D.; Chuck, S.; Enejosa, J.; Toole, J. J.; Cheng, A. K. Tenofovir DF, Emtricitabine, and Efavirenz vs Zidovudine, and Efavirenz for HIV N. Engl. J. Med. 2006, 354, 251-260 (Pubitemid 43113030)
14. Pozniak, A. L.; Gallant, J. E.; DeJesus, E.; Arribas, J. R.; Gazzard, B.; Campo, R. E.; Chen, S. S.; McColl, D.; Enejosa, J.; Toole, J. J; Cheng, A. K. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes-a 96-week analysis J. Acquired Immune Defic. Syndr. 2006, 43, 535-540 (Pubitemid 44885619)
15. Li, F.; Maag, H.; Alfredson, T. Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting J. Pharm. Sci. 2008, 97, 1109-1134
16. Agarwal, H. K.; Chhikara, B. S.; Hanley, M. J.; Ye, G.; Doncel, G. F.; Parang, K. Synthesis and biological evaluation of fatty acyl ester derivatives of (-)-2′,3′-dideoxy-3′-thiacytidine J. Med. Chem. 2012, 55, 4861-4871
17. Parang, K.; Knaus, E. E.; Wiebe, L. I. Synthesis, in vitro anti-HIV structure-activity relationships and stability of 5′- O -myristoyl analogue derivatives of 3′-azido-2′,3′-dideoxythymidine as potential prodrugs of 3′-azido-2′,3′-dideoxythymidine (AZT) Antiviral Chem. Chemother. 1998, 9, 311-323 (Pubitemid 28368253)
18. Parang, K.; Knaus, E. E.; Wiebe, L. I. Synthesis, in vitro anti-HIV activity, and biological stability of 5′- O -myristoyl analogue derivatives of 3′-fluoro-2′,3′-dideoxythymidine (FLT) as potential prodrugs of FLT Nucleosides Nucleotides 1998, 17, 987-1008 (Pubitemid 28232349)
19. Parang, K.; Wiebe, L. I.; Knaus, E. E.; Huang, J.-S.; Tyrrell, D. L.; Csizmadia, F. In vitro antiviral activities of myristic acid analogs against human immunodeficiency and hepatitis B viruses Antiviral Res. 1997, 34, 75-90 (Pubitemid 27220184)
20. Farazi, T. A.; Waksman, G.; Gordon, J. I. The biology and enzymology of protein N -myristoylation J. Biol. Chem. 2001, 276, 39501-39504
21. Langner, C. A.; Travis, J. K.; Caldwell, S. J.; Tianbao, J. E.; Li, Q.; Bryant, M. L.; Devadas, B.; Gokel, G. W.; Kobayashi, G. S.; Gordon, J. I. 4-Oxatetradecanoic acid is fungicidal for Cryptococcus neoformans and inhibits replication of human immunodeficiency virus I J. Biol. Chem. 1992, 267, 17159-17169
22. Bryant, M. L.; McWherter, C. A.; Kishore, N. S.; Gokel, G. W.; Gordon, J. I. MyristoylCoA:protein N-myristoyltransferase as a therapeutic target for inhibiting replication of human immunodeficiency virus-1 Perspect. Drug Dis. Des. 1993, 1, 193-209
23. Takamune, N.; Hamada, H.; Misumi, S.; Shoji, S. Novel strategy for anti-HIV-1 action: selective cytotoxic effect of N -myristoyltransferase inhibitor on HIV-1 infected cells FEBS Lett. 2002, 527, 138-142 (Pubitemid 35253854)
24. Morris, G. C.; Lacey, C. J. Microbicides and HIV prevention: lessons from the past, looking to the future Curr. Opin. Infect. Dis. 2010, 23, 57-63
25. Agarwal, H. K.; Kumar, A.; Doncel, G. F.; Parang, K. Synthesis, antiviral and contraceptive activities of nucleoside-sodium cellulose sulfate acetate and succinate conjugates Bioorg. Med. Chem. Lett. 2010, 20, 6993-6997
26. Krebs, F. C.; Miller, S. R.; Ferguson, M. L.; Labib, M.; Rando, R. F.; Wigdahl, B. Polybiguanides, particularly polyethylene hexamethylene biguanide, have activity against human immunodeficiency virus type 1 Biomed. Pharmacother. 2005, 59, 438-445 (Pubitemid 41383837)
27. Lackman-Smith, C. S.; Snyder, B. A.; Marotte, K. M.; Osterling, M. C.; Mankowski, M. K.; Jones, M.; Nieves-Duran, L.; Richardson-Harman, N.; Cummins, J. E., Jr.; Sanders-Beer, B. E. Safety and anti-HIV assessments of natural vaginal cleansing products in an established topical microbicides in vitro testing algorithm AIDS Res Ther. 2010, 7, 22
28. Buckheit, R. W., Jr.; Swanstrom, R. Characterization of an HIV-1 isolate displaying an apparent absence of virion-associated reverse transcriptase activity AIDS Res. Hum. Retroviruses 1991, 7, 295-302